Shares of Trillium Therapeutics (TRIL) have risen by 21% since my January article recommended scooping up shares of this "fast follower" in the potentially lucrative CD47 space.
With shares trying to break above the 50-day moving average ahead of what I call a "needle-moving" catalyst, I'm looking forward to update readers on this innovative, small-cap oncology player.
Chart
Figure 1: TRIL daily advanced chart (Source: Finviz)
When looking at charts, clarity often comes from taking a look at distinct time frames in order to determine important technical levels to get a feel for